Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 5/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484698 | 1.00 | MEN1 (0.48) | MEN1KMT2AACETAAR1ELANE | |
| SCHEMBL18620590 | 0.90 | ALDH1A1 (0.46) | MEN1KMT2ATAAR1ELANEPREP | |
| SCHEMBL22209415 | 0.90 | ALDH1A1 (0.46) | MEN1KMT2ATAAR1ELANEPREP | |
| SCHEMBL18620640 | 0.89 | MEN1 (0.47) | MEN1KMT2AACETAAR1ELANE | |
| SCHEMBL20485170 | 0.89 | MEN1 (0.47) | MEN1KMT2AACETAAR1ELANE | |
| SCHEMBL20484656 | 0.86 | PREP (0.53) | MEN1KMT2AACEELANEPREP | |
| SCHEMBL18619617 | 0.86 | PREP (0.53) | MEN1KMT2AACEELANEPREP | |
| SCHEMBL18619576 | 0.86 | PREP (0.42) | MEN1KMT2ATAAR1ELANEPREP | |
| SCHEMBL20485172 | 0.83 | PREP (0.50) | MEN1KMT2AACEELANEPREP | |
| SCHEMBL18620887 | 0.83 | PREP (0.50) | MEN1KMT2AACEELANEPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC) (US) | 2018-09-06 | — | — | US | disclosed |
| US-9490435-B2 | Iridium complex and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD (KR) | 2016-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | MALT1, BCL3, BCL6 | MEN1 203/4885KMT2A 2424/4885ACE 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.